Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets

Table 9

Summary of ANOVA results of the response surface quadratic model for friability and the linear model for disintegration time.

Responses	Source	Sum of squares	df	Mean square	F value	P value	Remark
Friability	Model	1.83	9	0.367	74.4	<0.0001	Significant
	A-PEG 6000	0.477	1	0.477	96.8	<0.0001	Significant
	C-compression force	0.583	1	0.583	118	<0.0001	Significant
	AC	0.0450	1	0.0450	9.14	0.00980	Significant
	A^2	0.0293	1	0.0293	5.95	0.0298	Significant
	C^2	0.725	1	0.725	147	<0.0001	Significant
	Residual	0.0640	13	0.00493			Significant
	Lack of fit	0.0594	9	0.00660	5.74	0.0539	Insignificant
	Pure error	0.00460	4	0.00115
	Core total	1.90	18
Disintegration time	Model	14868.94	3	4956.31	23.10	<0.0001	Significant
	A-PEG 6000	3075.78	1	3075.78	14.34	0.0018	Significant
	B-crospovidone	9796.39	1	9796.39	45.66	<0.0001	Significant
	C-compression force	1996.77	1	1996.77	9.31	0.0081	Significant
	Residual	3218.00	15	214.53
	Lack of fit	2936.80	11	266.98	3.80	0.1046	Insignificant
	Pure error	281.20	4	70.30
	Core total	18086.95	18